Trial Details
COMPLETEDBasic Information
| Clinical ID | c1102 |
|---|---|
| Identifier | NCT02318667 |
| Trial Title | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Colitis, Ulcerative |
| Interventions | BIOLOGICAL: Golimumab |
Participant Information
| Sponsor | Merck Sharp & Dohme LLC |
|---|---|
| City | - |
| Country/Region | - |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2015-02-27 |
|---|---|
| Primary Completion Date | 2017-06-21 |
| Completion Date | 2017-09-05 |